Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Nov
11
Today In Oncology
CTCL Denileukin Diftitox May Improve HRQoL
Anbenitamab/HB1801 vs THP in HER2-Positive Advanced Breast Cancer
KEYNOTE-867 Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC
FDA Approves Pimicotinib for Symptomatic TGCT
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo